Y
Yao Lu
Researcher at Vanderbilt University
Publications - 5
Citations - 330
Yao Lu is an academic researcher from Vanderbilt University. The author has contributed to research in topics: Fulvestrant & Tyrosine-kinase inhibitor. The author has an hindex of 3, co-authored 4 publications receiving 210 citations. Previous affiliations of Yao Lu include Vanderbilt University Medical Center.
Papers
More filters
Journal ArticleDOI
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Luigi Formisano,Yao Lu,Alberto Servetto,Ariella B. Hanker,Ariella B. Hanker,Valerie M. Jansen,Joshua A. Bauer,Dhivya R. Sudhan,Dhivya R. Sudhan,Angel Guerrero-Zotano,Sarah Croessmann,Yan Guo,Paula Gonzalez Ericsson,Kyungmin Lee,Mellissa J. Nixon,Luis J. Schwarz,Melinda E. Sanders,Teresa C. Dugger,Marcelo Rocha Cruz,Amir Behdad,Massimo Cristofanilli,Aditya Bardia,Joyce O'Shaughnessy,Rebecca J. Nagy,Richard B. Lanman,Nadia Solovieff,Wei He,Michelle Miller,Fei Su,Yu Shyr,Ingrid A. Mayer,Justin M. Balko,Carlos L. Arteaga,Carlos L. Arteaga +33 more
TL;DR: It is shown that FGFR1 amplification is a resistance mechanism to CDK4/6 inhibitor and endocrine therapy and that combined treatment with FGFR, CDK 4/6, and anti-estrogens is a potential therapeutic strategy in Era+ breast cancer tumors.
Journal ArticleDOI
Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer
Luigi Formisano,Luigi Formisano,Kimberly M. Stauffer,Christian D. Young,Neil E. Bhola,Angel Guerrero-Zotano,Valerie M. Jansen,Monica M. Estrada,Katherine E. Hutchinson,Jennifer M. Giltnane,Luis J. Schwarz,Yao Lu,Justin M. Balko,Olivier Deas,Stefano Cairo,Jean Gabriel Judde,Ingrid A. Mayer,Melinda E. Sanders,Teresa C. Dugger,Roberto Bianco,Thomas Stricker,Carlos L. Arteaga +21 more
TL;DR: The data suggest the ERα pathway remains active in estrogen-deprived ER+/FGFR1–amplified breast cancers, and these tumors are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists.
Proceedings ArticleDOI
Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer
Luigi Formisano,Yao Lu,Valerie M. Jansen,JA Bauer,Ariella B. Hanker,P Gonzalez Ericsson,KS Lee,MJ Nixon,AL Guerrero-Zotano,Luis J. Schwarz,Melinda Sanders,Dhivya R. Sudhan,Teresa C. Dugger,Cruz,Amir Behdad,Massimo Cristofanilli,Aditya Bardia,Joyce O'Shaughnessy,Ingrid A. Mayer,CL Arteaga +19 more
TL;DR: ER+/FGFR1 amplified breast cancers are endocrine resistant and should be candidates for treatment with combinations of ER and FGFR antagonists, and a phase Ib trial of fulvestrant, palbociclib and erdafitinib is initiated.
Journal ArticleDOI
Using a Gene Network of Pyroptosis to Quantify the Responses to Immunotherapy and Prognosis for Neuroblastoma Patients
Bi Luo,Limin Wang,Wei-Qiang Gao,Yudong Su,Yao Lu,Jian Zheng,Jie Yin,Qiang Zhao,Jie Li,Yurong Da,Long Li +10 more
TL;DR: It is revealed that pyroptosis-related gene network could quantify the response of neuroblastoma to immune checkpoint blockade therapy and prognosis, and it may be helpful for clinical practitioners to choose treatment strategies for Neuroblastoma patients.
Journal ArticleDOI
Correction: Association of FGFR1 with ERA maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER þ breast cancer (Clinical Cancer Research (2019)23 (6138–6150) Doi:10.1158/1078-0432.CCR-17-1232)
Luigi Formisano,Kimberly M. Stauffer,Christian D. Young,Neil E. Bhola,L. Guerrero Zotano Angel,Valerie M. Jansen,Monica M. Estrada,Katherine E. Hutchinson,Jennifer M. Giltnane,Luis J. Schwarz,Yao Lu,Justin M. Balko,Olivier Deas,Stefano Cairo,Jean Gabriel Judde,Ingrid A. Mayer,Melinda E. Sanders,Teresa C. Dugger,Roberto Bianco,Thomas Stricker,Carlos L. Arteaga +20 more